GW 471558

an azasordarin with 6-methylmorpholin-2-yl group with different N-4' substituents at position 8a of the sordaricin indacene ring system; inhibits protein synthesis elongation cycle

Also Known As:

GW-471558; GW471558

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Indenes: 4
        GW 471558: 2
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Indenes: 4
    - GW 471558: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - Morpholines: 6
      - GW 471558: 2

Experts

1.	Aliouat, El Moukhtar: 1 article (08/2002)
2.	Caballero, Jesus: 1 article (08/2002)
3.	Dei-Cas, Eduardo: 1 article (08/2002)
4.	Gargallo-Viola, Domingo: 1 article (08/2002)
5.	Jimenez, Elena: 1 article (08/2002)
6.	Martínez, Antonio: 1 article (08/2002)
7.	De Las Heras, F G: 1 article (12/2001)
8.	Ferrer, S: 1 article (12/2001)
9.	Gargallo-Viola, D: 1 article (12/2001)
10.	Jimenez, E: 1 article (12/2001)

Related Diseases

1.	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 08/01/2002 - "Two new azasordarins, GW471552 and GW471558, were studied in vivo for treatment of Pneumocystis carinii pneumonia. " 08/01/2002 - "Therapeutic efficacies of GW471552 and GW471558, two new azasordarin derivatives, against pneumocystosis in two immunosuppressed-rat models."
2.	Infections 12/01/2001 - "In the oral infection model, GW471552 and GW471558 administered at 5 mg/kg significantly reduced (P < 0.05) the number of CFU of C. "
3.	Vulvovaginal Candidiasis 12/01/2001 - "The therapeutic efficacies of two new azasordarins, GW471552 and GW471558, were studied in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats. " 12/01/2001 - "Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats."
4.	Body Weight (Weight, Body) 12/01/2001 - "GW471552 and GW471558 were administered at 1, 5, and 10 mg/kg of body weight via the subcutaneous route. "